PMID- 19786664
OWN - NLM
STAT- MEDLINE
DCOM- 20100105
LR  - 20151119
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 27
IP  - 33
DP  - 2009 Nov 20
TI  - Immuno-fluorescence in situ hybridization index predicts survival in patients 
      with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
PG  - 5573-9
LID - 10.1200/JCO.2009.22.7058 [doi]
AB  - PURPOSE: To evaluate the prognostic value of cell of origin immunohistochemical 
      markers and BCL2, BCL6, and c-MYC translocations in a homogeneous cohort of 
      patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus 
      cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). PATIENTS AND 
      METHODS: Patients with CD20+ DLBCL were enrolled in the randomized LNH98-5 and 
      01-5B Groupe d'Etude des Lymphomes de l'Adulte trials. Paraffin-embedded tumor 
      samples of 119 patients treated with R-CHOP were analyzed by immunohistochemistry 
      for CD10, BCL6, MUM1/IRF4, LMO2, and forkhead box protein P1 (FOXP1) expression 
      and for BCL2, BCL6, and c-MYC breakpoints by fluorescence in situ hybridization 
      (FISH) on tissue microarray. RESULTS: LMO2 expression and BCL2 breakpoint were 
      associated with the germinal center (GC) subtype defined by Hans' algorithm, 
      respectively (P < .0001; P = .0002) whereas FOXP1 expression and BCL6 breakpoint 
      were associated with the non-germinal center (non-GC) subtype (P = .008 and P = 
      .0001, respectively). The immunohistochemical markers analyzed independently, 
      GC/non-GC phenotype and BCL2 breakpoint did not predict overall survival (OS). 
      BCL6 breakpoint was significantly associated with an unfavorable impact on OS (P 
      = .04). Interestingly, an immunoFISH index, defined by positivity for at least 
      two of three non-GC markers (FOXP1, MUM1/IRF4, BCL6 breakpoint) was significantly 
      associated with a shorter 5-year OS rate (44%; 95% CI, 28 to 60 v 78%; 95% CI, 59 
      to 89; P = .01) which was independent (P = .04) of the age-adjusted International 
      Prognostic Index (P = .04) in multivariate analysis. CONCLUSION: Our study 
      demonstrates that combining immunohistochemistry with FISH allows construction of 
      an immunoFISH index that significantly predicts survival in elderly DLBCL 
      patients treated with R-CHOP.
FAU - Copie-Bergman, Christiane
AU  - Copie-Bergman C
AD  - Assistance Publique-Hopitaux de Paris, Groupe Henri Mondor-Albert Chenevier, 
      L'Institut National de la Sante et de la Recherche Medicale, Unite 955, Institut 
      Mondor de Recherche Biomedicale; Universite Paris 12, Faculte de medecine, 
      Creteil. christiane.copie@hmn.aphp.fr
FAU - Gaulard, Philippe
AU  - Gaulard P
FAU - Leroy, Karen
AU  - Leroy K
FAU - Briere, Josette
AU  - Briere J
FAU - Baia, Maryse
AU  - Baia M
FAU - Jais, Jean-Philippe
AU  - Jais JP
FAU - Salles, Gilles A
AU  - Salles GA
FAU - Berger, Francoise
AU  - Berger F
FAU - Haioun, Corinne
AU  - Haioun C
FAU - Tilly, Herve
AU  - Tilly H
FAU - Emile, Jean-Francois
AU  - Emile JF
FAU - Banham, Alison H
AU  - Banham AH
FAU - Mounier, Nicolas
AU  - Mounier N
FAU - Gisselbrecht, Christian
AU  - Gisselbrecht C
FAU - Feugier, Pierre
AU  - Feugier P
FAU - Coiffier, Bertrand
AU  - Coiffier B
FAU - Molina, Thierry J
AU  - Molina TJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090928
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Biomarkers)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Biomarkers/blood
MH  - Cyclophosphamide
MH  - Dose-Response Relationship, Drug
MH  - Doxorubicin
MH  - Drug Administration Schedule
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - *Genes, myc
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/*immunology/*mortality
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prednisone
MH  - Probability
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-bcl-2/*analysis
MH  - Risk Assessment
MH  - Rituximab
MH  - Severity of Illness Index
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vincristine
EDAT- 2009/09/30 06:00
MHDA- 2010/01/06 06:00
CRDT- 2009/09/30 06:00
PHST- 2009/09/30 06:00 [entrez]
PHST- 2009/09/30 06:00 [pubmed]
PHST- 2010/01/06 06:00 [medline]
AID - JCO.2009.22.7058 [pii]
AID - 10.1200/JCO.2009.22.7058 [doi]
PST - ppublish
SO  - J Clin Oncol. 2009 Nov 20;27(33):5573-9. doi: 10.1200/JCO.2009.22.7058. Epub 2009 
      Sep 28.